Friday, July 10, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

BG00012

Phase 3 · small molecule · Relapsing-Remitting Multiple Sclerosis

BG00012 for Relapsing-Remitting Multiple Sclerosis is a Phase 3 program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Phase 3 small molecule completed

Internal code 109MS301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Phase 3
Modality
small_molecule
Indication
Relapsing-Remitting Multiple Sclerosis
Status
completed
Trials
1